Hemostatic Disorders on Intensive Care Patients.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04179357|
Recruitment Status : Unknown
Verified November 2019 by Mohamed Fawzi Ibrahim Mansour, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : November 27, 2019
Last Update Posted : November 27, 2019
- To assess the incidence of hemostatic disorders among ICU patients.
- To establish a relationship between supportive treatment and survival in patients with coagulopathy in ICU.
- To provide solutions that can help in reduction of the incidence of hemostatic disorders in ICU patients.
|Condition or disease|
Hemostasis is the physiological process that stops bleeding at the site of an injury while maintaining normal blood flow elsewhere in the circulation. Blood loss is stopped by formation of a hemostatic plug. The endothelium in blood vessels maintains an anticoagulant surface that serves to maintain blood in its fluid state, but if the blood vessel is damaged components of the subendothelial matrix are exposed to the blood. Several of these components activate the two main processes of hemostasis to initiate formation of a blood clot, composed primarily of platelets and fibrin.
Many critically ill patients develop hemostatic abnormalities, ranging from isolated thrombocytopenia to complex defects, such as DIC. Coagulation abnormalities are commonly found in critically ill patients. Prompt and proper identification of the underlying cause of these coagulation abnormalities is required, since each coagulation disorder necessitates very different therapeutic management strategies.
Management of coagulopathy The key basic management principle of all coagulopathies is that the decision to transfuse blood products should not be based on the results of coagulation tests alone, rather an individualized approach is warranted. It is imperative to synthesizes all the available clinical data and treat the underlying cause.
In summary, hemostatic disorders are very common in the critically ill. Blood product support is frequently required, but there is only a very limited evidence-base to support its use. In many cases, no specific product support is required and the key management step is the treatment of the condition underlying the coagulopathy .
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Hemostatic Disorders Impact on Intensive Care Patients.|
|Estimated Study Start Date :||January 2020|
|Estimated Primary Completion Date :||September 2020|
|Estimated Study Completion Date :||September 2020|
- Describe the Pattern of Homeostasis Disorders occur in Critical Care Unit in Assiut University [ Time Frame: Baseline ]Study the causes of either bleeding or thrombotic events in Critical care unit. Describe the pattern of the disease regarding age, sex and predisposing factors.
- Correlate Supportive and Definitive Treatment and Outcomes of Patients with Homeostasis Disorder in ICU. [ Time Frame: Baseline ]Study the forms of transfusion ( e.g.packed red blood cells, Platelet , Fresh frozen plasma), anti bleeding measures (e.g. Tranexamic acid), anticoagulant and anti platelet drugs received by the patients and their outcomes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04179357
|Contact: Mohamed Fawzi Ibrahim, Masteremail@example.com|